title: Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
abstract: Allogeneic hematopoietic stem cell transplantation (SCT) is a widely used, cost-intensive procedure. Although pretransplant nonmyeloablative (NMA) or reduced-intensity conditioning regimens appear very promising, prospective studies comparing this approach with the conventional myeloablative (MA) approach in specific hematologic diseases are necessary, especially in patients in whom the conventional approach is not contraindicated. Cost may be an important factor in the decision-making process. We compared the costs of MA and NMA transplants in patients with acute myeloid leukemia (AML). We estimated 1-year resource utilization in 12 consecutive MA patients (median age: 39 years) and in 11 consecutive NMA patients (median age: 58 years) who underwent HLA-identical sibling SCT for AML. Resources care expenses were valued using the average daily rate for personnel costs, supplies, and room costs. Other data were directly collected from the patients' charts. Despite a trend for lower costs in NMA patients during the first 6 months, costs during the 6-12-month period were significantly higher after NMA due to late complications and readmissions (P=0.03). Finally, mean 1-year costs were not different in MA and NMA patients (P=0.75). Prospective studies comparing conventional and NMA approaches in homogeneous populations should include economic items.
authors.affiliation: Service d'Hématologie clinique, CHU Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France. carlcord@club-internet.fr
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: S
authors.initials: S
authors.lastname: Maury
authors.forename: H
authors.initials: H
authors.lastname: Esperou
authors.forename: C
authors.initials: C
authors.lastname: Pautas
authors.forename: J
authors.initials: J
authors.lastname: Beaune
authors.forename: M
authors.initials: M
authors.lastname: Rodet
authors.forename: J-L
authors.initials: JL
authors.lastname: Lagrange
authors.forename: H
authors.initials: H
authors.lastname: Rouard
authors.forename: J-L
authors.initials: JL
authors.lastname: Beaumont
authors.forename: F
authors.initials: F
authors.lastname: Bassompierre
authors.forename: E
authors.initials: E
authors.lastname: Glückman
authors.forename: M
authors.initials: M
authors.lastname: Kuentz
authors.forename: I
authors.initials: I
authors.lastname: Durand-Zaleski
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000191:economics*; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000191:economics*